Life Science Investing Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Life Science Investing Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Life Science Investing Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Life Science Investing Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Revolve Receives Approval from the Alberta Utilities Commission for the 15.7 MW Bright Meadows Solar Project
Terra Clean Energy Corp. Announces Agreement to Earn 100% Interest in 75 Past Producing Uranium Claims on The San Rafael Swell, Utah, United States
